Pexidartinib (PLX-3397)是一种口服有效的选择性CSF1R和c-Kit抑制剂,其对c-Kit和CSF1R的选择性是对FLT3、KDR等其他激酶的10-100倍,并能通过诱导细胞凋亡发挥抗肿瘤活性。
|
英文别名 (English Synonym) |
Pexidartinib (PLX3397) |
|
中文名称 (Chinese Name) |
培西达替尼 |
|
靶点 (Target) |
CSF-1R |
|
通路 (Pathway) |
Protein Tyrosine Kinase |
|
CAS号 (CAS NO.) |
1029044-16-3 |
|
分子式 (Formula) |
C20H15ClF3N5 |
|
分子量 (Molecular Weight) |
417.81 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
易溶于DMSO |
-25~-15℃保存，有效期3年
[1] DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011 Jun,1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1. PMID: 22039576, PMCID: PMC3203524.[2]Kuse Y, Ohuchi K, Nakamura S, Hara H, Shimazawa M. Microglia increases the proliferation of retinal precursor cells during postnatal development. Mol Vis. 2018 Jul 30,24:536-545. PMID: 30090016, PMCID: PMC6066272.
